The fact that BCA2 fails at inducing the anti-tumor function of IRF1 in the MDA-MB-231 ER– cell line is consistent with the aggressive nature of these tumor cells, which may have evolved mechanisms to override BCA2 actions. The gene discussed is IRF1; the disease is neoplasm.